Starling Oncology Warrant
STLNW
14 hedge funds and large institutions have $19K invested in Starling Oncology Warrant in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 6 reducing their positions, and 2 closing their positions.
1.3% more ownership
Funds ownership: 3.44% → 4.74% (+1.3%)
7% less funds holding
Funds holding: 15 → 14 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
63% less capital invested
Capital invested by funds: $52K → $19K (-$33K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LP
LMR Partners
London,
United Kingdom
|
+$25.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$5.3K |
| 2 |
FL
FreeGulliver LLC
New Orleans,
Louisiana
|
-$2.72K |
| 3 |
Two Sigma Investments
New York
|
-$600 |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$85 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$46 |
STLNW Hedge Fund Activity: Q4 2024 in Review
14 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology Warrant (STLNW) for Q4 2024, worth a combined $19K — down 63% from $52K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of STLNW and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 0 added.
The largest buyer was LMR Partners, opening a new position worth an estimated $25.3K. The largest seller was Walleye Capital, cutting an estimated $5.3K.
- 14 institutional investors held Starling Oncology Warrant (STLNW) as of Q4 2024, down from 15 in Q3 2024.
- Funds reported $19K of Starling Oncology Warrant stock for Q4 2024, down 63% quarter-over-quarter.
- 1 fund opened new Starling Oncology Warrant positions in Q4 2024 and 2 closed out, a net change of -1 holder.
- The largest Starling Oncology Warrant buyer in Q4 2024 was LMR Partners, an estimated $25.3K added.
- The largest Starling Oncology Warrant seller in Q4 2024 was Walleye Capital, an estimated $5.3K sold.
Based on aggregated 13F filings for Q4 2024.